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Abstract How tissue-resident macrophages (TRM) impact adaptive immune responses remains
poorly understood. We report novel mechanisms by which TRMs regulate T cell activities at tissue
sites. These mechanisms are mediated by the complement receptor of immunoglobulin family
(CRIg). Using animal models for autoimmune type 1 diabetes (T1D), we found that CRIg+ TRMs
formed a protective barrier surrounding pancreatic islets. Genetic ablation of CRIg exacerbated
islet inflammation and local T cell activation. CRIg exhibited a dual function of attenuating early T
cell activation and promoting the differentiation of Foxp3+ regulatory (Treg) cells. More
importantly, CRIg stabilized the expression of Foxp3 in Treg cells, by enhancing their
responsiveness to interleukin-2. The expression of CRIg in TRMs was postnatally regulated by gut
microbial signals and metabolites. Thus, environmental cues instruct TRMs to express CRIg, which
functions as an immune checkpoint molecule to regulate adaptive immunity and promote immune
tolerance.
DOI: https://doi.org/10.7554/eLife.29540.001
Introduction
Most complex diseases are associated with a tissue-specific chronic inflammation. Excessive inflam-
mation has deleterious consequences, characterized by tissue damage and disease onset (Medzhi-
tov, 2008; Grivennikov et al., 2010; Olefsky and Glass, 2010). Understanding cellular and
molecular mechanisms that can keep inflammation in check will have important therapeutic implica-
tions in autoimmune and inflammatory diseases. Macrophages, especially tissue-resident populations
(TRMs) represent a key constituent of the innate immune system in orchestrating inflammation and
influencing the functions of other immune and non-immune cells (Medzhitov, 2008; Davies et al.,
2013). In concert with other innate immune cells (e.g., mast cells), macrophages sense environmental
stimuli and subsequently instruct adaptive immunity (primarily T cells), together to elicit the pro-
cesses of host defense and tissue repair (Iwasaki and Medzhitov, 2015).
Under autoimmune conditions, self-reactive T cells accumulate at tissue sites and lead to tissue
destruction. T cell activities need to be restrained to maintain immunological tolerance (Sharpe and
Freeman, 2002). However, how these autoimmune T cell responses are influenced by tissue micro-
environment remains poorly understood. We hypothesize that macrophages, especially TRMs may
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fulfill such a role to modulate tissue T cell activities. Multiple mechanisms may be exploited by these
TRMs to regulate T cell activities. First, these TRMs express multiple coinhibitory molecules of B7/
CD28 and TNFR families, such as PD-L1, PD-1 and TIM-4 (refs [Kuang et al., 2009; Gordon et al.,
2017; Thornley et al., 2014]). Second, TRMs may regulate the generation, stability, and function of
Foxp3+ regulatory T (Treg) cells. This notion is supported by a few studies (Denning et al., 2007;
Soroosh et al., 2013; Haribhai et al., 2016). These studies have demonstrated that macrophages
residing in the lung (Soroosh et al., 2013), or intestinal lamina propria (Denning et al., 2007;
Haribhai et al., 2016) can promote the generation of Treg cells. These two mechanisms are not
mutually exclusive, because certain coinhibitory molecules (e.g., PD-L1) have been found to promote
the generation of Treg cells (Francisco et al., 2009; Wang et al., 2008; Amarnath et al., 2011).
Recently, a new subset of TRMs has been identified (Helmy et al., 2006; Vogt et al., 2006;
Fu et al., 2012). These macrophages are phenotypically characterized as CD11b+ F4/80hi CRIg+.
CRIg+ macrophages can be detected in peritoneal cavity and most digestive organs, including pan-
creas, liver, small and large intestines (Helmy et al., 2006; Vogt et al., 2006; Fu et al., 2012;
Gautier et al., 2012). Macrophages from lymphoid organs do not express CRIg. CRIg is also absent
in other immune cells, including T cells, B cells, NK cells, dendritic cells, monocytes, and neutrophils
(Helmy et al., 2006; Vogt et al., 2006). Thus, the expression of CRIg is restricted to TRMs. CRIg
(gene symbol: Vsig4) was previously reported as a complement receptor (Helmy et al., 2006). It
binds to complement components C3b, iC3b and C3c, and is involved in the phagocytosis of
microbes (Helmy et al., 2006; Wiesmann et al., 2006). However, further studies including ours,
have revealed that CRIg can function as a coinhibitory molecule of the B7/CD28 superfamily
(Vogt et al., 2006; Fu et al., 2012). In this regard, CRIg potently suppresses T cell proliferation and
cytokine production (Vogt et al., 2006; Fu et al., 2012). Given that CRIg is exclusively expressed by
TRMs, we propose that CRIg mediated signaling represents a tissue-derived mechanism by which
resident macrophages regulate tissue homeostasis and inflammatory processes.
In autoimmune type 1 diabetes (T1D), islet inflammation (insulitis) is exacerbated by the loss-of-
balance between regulatory and pathogenic immune cells (Bluestone et al., 2010). However, not all
individuals with insulitis proceed to become diabetic, suggesting that there exist mechanisms that
can keep insulitis in check. We have previously found that the abundance of CRIg+ macrophages in
the pancreas was negatively correlated with the risk of diabetes onset in non-obese diabetic (NOD)
mice, the primary animal model for T1D. More importantly, in vivo administration of CRIg-Ig fusion
protein suppressed diabetes in these mice (Fu et al., 2012). In this study, we attempted to under-
stand how CRIg impacts T cell activities using mouse T1D as a primary model system. Our studies
revealed a dual role of CRIg in regulating effector T cell proliferation and Treg differentiation and
stability. Together, these two outcomes led to a reinforced immune tolerance in NOD mice. Further-
more, we investigated the role of gut microbiota and derived metabolites in regulating the expres-
sion of CRIg in TRMs. Together, these findings support a new model of immune regulation in tissue
homeostasis whereby environmental cues instruct TRMs to express CRIg, which functions as an
immune checkpoint molecule to regulate adaptive immunity and promote immune tolerance.
Results
CRIg+ TRMs form a protective barrier surrounding pancreatic islets to
prevent autoimmune infiltration in NOD mice
CRIg is exclusively expressed in TRMs (Helmy et al., 2006; Vogt et al., 2006; Fu et al., 2012).
CRIg+ macrophages can be detected in most digestive organs at steady state, including the pan-
creas, liver, colon and peritoneal cavity of both C57BL/6 (B6) and NOD mice (Figure 1-figure sup-
plement 1A, B and data not shown). CRIg+ cells was also found in human pancreas (Figure 1—
figure supplement 1C). There was no CRIg+ cell in the lung in both mouse strains (Figure 1—figure
supplement 1A and B and data not shown). The expression of CRIg was not detected in lymphoid-
lineage cells, including T cells, B cells and NK cells (Figure 1—figure supplement 1D). In the pan-
creas, CRIg+ TRMs were enriched at the capsular area of the islets (Figure 1—figure supplement
1A), exhibiting a perivascular distribution (Fu et al., 2012). We have previously found that the abun-
dance of islet CRIg+ macrophages in NOD mice was negatively correlated with the risk of diabetes
onset in these animals (Fu et al., 2012), suggesting a disease-suppressing role of CRIg+ TRMs in
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T1D. However, the mechanisms remained undefined. Given the unique tissue distribution pattern of
these cells, we examined the relationship between the severity of insulitis and the abundance of
peri-islet CRIg+ TRMs on a per-islet basis in pre-diabetic NOD mice. We found that intact islets (free
from autoimmune infiltration) were associated with more abundant peri-islet CRIg+ TRMs. In con-
trast, in insulitic islets, there was a lack of CRIg expression in TRMs, especially in those peri-islet
areas succumbed to infiltration (Figure 1A). These results suggest that CRIg+ TRMs may function as
a local barrier to prevent immune infiltration into pancreatic islets. We proposed that CRIg molecule
was critical for these TRMs to exhibit such a protective role in insulitis. To confirm the role of CRIg,
we generated CRIg-null mutation onto a NOD background. Indeed, genetic ablation of CRIg
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Figure 1. CRIg+TRMs form a protective barrier to prevent tissue autoimmune infiltration and activation. (A) The distribution of CRIg+ TRMs within the
pancreas. Immunostaining of pancreatic frozen sections of 10-week-old NOD mice. (left) Representative images depicting an intact (upper) and an
insulitic (lower) islet, respectively. Red: CRIg; Blue: DAPI. The border of the islet was marked by dotted lines; immune infiltration was highlighted by
higher density of DAPI+ dots (n = 9 for intact and n = 8 for insulitic). Bar, 50 um. (right) The numbers of CRIg+ TRMs per islet counted from
immunostaining sections of pancreas as in (A). Islets were categorized into intact (free from infiltration) and insulitic groups. (B) The severity of insulitis in
10-week-old NOD and NOD/CRIg KO mice. Hematoxylin and eosin staining of pancreatic paraffin sections. Arrowheads depict massive immune
infiltration. Bar, 50 um. (C) Flow cytometric analyses of digested pancreases of NOD/CRIg KO mice and littermate controls (n = 7 in each group). (Left)
The percentages of pancreatic Treg cells in age-matched NOD and NOD/CRIg KO mice (mixed of both females and males). (Right) The ratio between
Treg cells and CD8+ T cells (n = 7 in each group). (D) The production of IFN-g in CD4+ Tconv and CD8+ T cells. Pancreatic digestions were the same as
in (C). Data are representative of three (A, B) or four (C, D) experiments. Student’s t-test was used. *p<0.05; **p<0.01; ***p<0.001.
DOI: https://doi.org/10.7554/eLife.29540.002
The following figure supplements are available for figure 1:
Figure supplement 1. Tissue-distribution of CRIg+ TRMs.
DOI: https://doi.org/10.7554/eLife.29540.003
Figure supplement 2. CRIg deficiency does not affect T cells in lymphoid organs.
DOI: https://doi.org/10.7554/eLife.29540.004
Figure supplement 3. Cell-cell contact between CRIg+TRMs and T cells in pancreas.
DOI: https://doi.org/10.7554/eLife.29540.005
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significantly exacerbated the severity of insulitis, reflected by a massive infiltration of leukocytes in
most islets (Figure 1B), supporting a critical role of CRIg for these CRIg+ TRMs to suppress insulitis.
This was consistent with our previously published observations showing that the lower the number
of pancreatic CRIg+ TRMs, the higher the incidence of diabetes in NOD mice (Fu et al., 2012).
We next asked whether CRIg deficiency in TRMs was correlated with altered compositions and
activities of islet T cells. Due to the heterogeneities of insulitis in NOD mice, we calculated the ratios
between regulatory and pathogenic cells in pancreatic islets to more accurately reflect how CRIg
deficiency affected the severity of insulitis within each individual mouse. Comparing to age-matched
wildtype NOD mice, CRIg knockout (KO) mice exhibited an altered balance between regulatory and
effector T cells, reflected by: (i) The fraction of Treg cells was reduced in pancreatic islets
(Figure 1C). Such a reduction of Treg abundance was not seen in lymphoid organs (Figure 1—figure
supplement 2), supporting a tissue-specific immunoregulatory role of CRIg. (ii) The ratio between
pancreatic Treg and CD8+ T cells was also reduced in NOD/CRIg KO mice (Figure 1C). We next ana-
lyzed cytokine production in T cells isolated from NOD/CRIg KO and littermate control mice. Both
CD4+ and CD8+ T cells isolated from the pancreatic islets, not lymphoid organs, of NOD/CRIg KO
mice exhibited significantly increased production of IFN-g (Figure 1D), which is a key pathogenic
cytokine in T1D development (Feuerer et al., 2009). We next examined whether CRIg+ TRMs inter-
acted with T cells. Immunostaining of pre-diabetic islets (with ongoing insulitis) from NOD mice
showed that there were cell clusters containing both CRIg+ TRMs and T cells in close proximity, sug-
gesting a cell-cell contact between CRIg+ TRMs and T cells (Figure 1—figure supplement 3).
In summary, pancreatic CRIg+ TRMs form a protective barrier surrounding the islets to prevent
insulitis and impact local immuno-balance between effector and regulatory T cells. CRIg molecule
plays a central role for these TRMs to exert their diabetes-suppressing effect.
CRIg suppresses T cell proliferation by attenuating early T cell
activation signaling
CRIg has been reported to suppress T cell activation and cytokine production (Vogt et al., 2006;
Fu et al., 2012). However, how CRIg regulates T cell activities remains unknown. Consistent with
previous reports (Vogt et al., 2006; Fu et al., 2012), we found that plate-coated CRIg-Ig, not con-
trol Ig, suppressed T cell proliferation in vitro (Figure 2A). We asked whether CRIg affected early
activation phase, or late proliferation phase, of T cells. To answer this question, we isolated CD4+
CD25- conventional T (Tconv) cells and cultured them in vitro for 3 days with anti-CD3/CD28. These
cultured T cells were supplemented with plate-coated CRIg-Ig under two different conditions - either
only the first 24 hours (hr), or only the late 48 hr, of the in vitro culture. We found that the presence
of CRIg-Ig during the first 24 hr was sufficient to suppress T cell proliferation, to an extent similar to
the condition where CRIg-Ig was present all time of the culture (Figure 2A). In contrast, when CRIg-
Ig was only present during the last 48 hr, its suppressive effect on T cell proliferation was largely
abolished (Figure 2A). Therefore, CRIg interferes early T cell activation. This notion was further sup-
ported by flow cytometric analysis of the expression of CD69 and CD25, two cell-surface markers
depicting T cell activation. In a time-course assay, the majority of T cells exhibited an upregulation of
both CD69 and CD25 within 17 hr. CRIg-Ig potently suppressed the upregulation of both CD69 and
CD25 in T cells (Figure 2B). We then examined whether CRIg affected TCR signaling pathways.
Using phosphorylation assays, we found that the presence of plate-bound CRIg-Ig suppressed the
phosphorylation of ZAP70, ERK1/2, AKT and ribosomal protein S6 (Figure 2C). These data suggest
that CRIg-Ig dampens several pathways that are crucial for early T cell activation, including the most
proximal signaling complex (ZAP70), the ERK-MAPK pathway (ERK1/2, and S6) and the AKT-MTOR
pathway (AKT, S6).
CRIg has also been reported as a complement receptor that binds to C3b, iC3b and C3c
(Helmy et al., 2006). We asked whether complement components were involved in CRIg elicited T
cell suppression. Using a specific monoclonal antibody (mAb) (clone 14G8) (ref. [Gorgani et al.,
2008]) that can block the binding of CRIg to C3 components, we found that 14G8 did not abolish T
cell suppression by CRIg, suggesting that complements were not involved in CRIg-mediated T cell
suppression (Figure 2—figure supplement 1A). This notion was further supported by that CRIg can
attenuate TCR activation in serum-free condition, which was deprived of complements (Figure 2—
figure supplement 1B). In fact, CRIg-Ig mediated suppression of T cell proliferation was even
enhanced by anti-CRIg (e.g., clone 14G8) (Figure 2—figure supplement 1A), or other clonotypes of
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Figure 2. CRIg suppresses T cell activation. (A) CFSE-labeled CD4+ CD25- Tconv cells were stimulated with anti-CD3/CD28. Plate-bound CRIg-Ig, or
control Ig, was added either all time during T cell culture (3 d), or only the first 24 hr, or the late 48 hr. T cell proliferation was measured by CFSE
dilution. (B) The expression of early T cell activation markers-CD69 and CD25 in cultured Tconv cells with plate-bound control Ig, or CRIg-Ig. (C) The
phosphorylation of early T cell activation cascade proteins. CD4+ CD25- Tconv cells were activated in vitro with anti-CD3/CD28 in the presence of plate-
Figure 2 continued on next page
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anti-CRIg mAbs that do not interfere the binding of CRIg to C3 components (data not shown), sug-
gesting a possible cross-linking effect by anti-CRIg mAbs on CRIg-Ig. In line with this, we found that
soluble CRIg-Ig did not suppress T cell proliferation. In contrast, pre-coating the plates with anti-
CRIg mAb (clone 14G8, or 17C9) enabled soluble CRIg-Ig to potently suppress T cell proliferation
(Figure 2—figure supplement 2).
We then asked whether CRIg can directly bind to T cells. In this regard, isolated CD4+ Tconv cells
were activated in vitro with anti-CD3/CD28 and cultured for various lengths of time (12, 24, and 72
hr, respectively). At each stage of T cell activation, these cells were incubated with biotinylated
CRIg-Ig or control Ig at 37˚C for 1 hr, and the binding was measured using a streptavidin-conjugated
secondary Ab. We found that CRIg can bind to activated T cells, in a dose-dependent manner
(Figure 2D). Interestingly, we observed stronger binding of CRIg-Ig to T cells at their early, not late,
stage of in vitro activation (12 hr and 24 hr versus 72 hr) (Figure 2D). This was consistent with the
suppressive effect of CRIg-Ig on T cells (Figure 2A). CRIg-Ig can also bind to activated Treg cells.
However, in any analyzed concentration of CRIg-Ig, or time-point, the binding intensity was lower
comparing to that for Tconv cells (Figure 2—figure supplement 3A). Consistent with this, Treg cells
were less sensitive to CRIg-mediated suppression (Figure 2—figure supplement 3B).
The extracellular domains of CRIg contain one IgV-type of immunoglobulin (Helmy et al., 2006;
Vogt et al., 2006). Without knowing the cognate receptor(s) for CRIg, we tested whether CRIg
could bind to any known coinhibitory molecules of immunoglobulin family. In a competition assay,
CD4+ Tconv cells were activated with anti-CD3/CD28 in the presence of plate-bound CRIg-Ig, or
control Ig. Based on the availabilities of Ig fusion proteins, we tested CTLA-4, PD-1, VISTA, CD226
and TIGIT to assess whether the soluble forms of any of these proteins can block the effect of CRIg-
Ig on T cell proliferation. None of these tested soluble proteins exhibited a blocking effect (Fig-
ure 2—figure supplement 4).
In summary, CRIg preferentially suppresses effector T cells via binding to a putative receptor in
these cells at their early stage of activation and attenuating early TCR activation signaling.
CRIg enhances iTreg differentiation in vitro and regulates pTreg
development at tissue sites
B7/CD28 family coinhibitory molecules (e.g., PD-L1) have been reported to promote Treg differenti-
ation (Francisco et al., 2009; Wang et al., 2008; Amarnath et al., 2011). We asked whether CRIg
has a similar effect on Treg differentiation. We assessed this possibility in an in vitro TGF-b - induced
Treg (iTreg) condition (Chen et al., 2003). Purified CD4+ Foxp3(GFP)- Tconv cells from the spleen
and LNs of NOD/Foxp3GFP mice (Haribhai et al., 2007) were cultured in the presence of anti-CD3/
CD28, IL-2 and TGF-b to induce iTreg differentiation. As expected, TGF-b promoted iTreg differenti-
ation in a dose-dependent manner. At any given dose of TGF-b, CRIg-Ig further enhanced the
Figure 2 continued
bound control Ig, or CRIg-Ig. (D) The binding of CRIg to activated T cells. CD4+ CD25- Tconv cells were activated in vitro by anti-CD3/CD28 for various
lengths of time (12 hr, 24 hr and 72 hr). At each time-point of T cell activation, various concentrations of biotinylated control Ig or CRIg-Ig were
incubated with T cells at 37˚C for 1 hr. The binding of biotin-labeled Ig proteins was detected using streptavidin-conjugated antibody. (left)
Representative histograms of SA-PercpCy5.5 MFIs depicting the binding intensities of biotinylated proteins (25 ug/ml) bound to T cells. (right) Statistical
data showing fold-changes of SA-PercpCy5.5 MFIs between CRIg-Ig and control Ig at each time-point and each concentration. P values were calculated
by comparing the binding intensities between biotin-CRIg-Ig and biotin-control-Ig. The data are representative from five (A), three (B), and four (C, D)
experiments. Student’s t-test was used. *p<0.05; **p<0.01; ***p<0.001, n.s., non-significant.
DOI: https://doi.org/10.7554/eLife.29540.006
The following figure supplements are available for figure 2:
Figure supplement 1. The suppressive effect of CRIg on T cells is complement-independent.
DOI: https://doi.org/10.7554/eLife.29540.007
Figure supplement 2. Plate-bound anti-CRIg mAb augments the effect of CRIg-Ig in T cells.
DOI: https://doi.org/10.7554/eLife.29540.008
Figure supplement 3. The binding of CRIg to activated Treg cells and differential suppression of CRIg-Ig for Tconv and Treg cells.
DOI: https://doi.org/10.7554/eLife.29540.009
Figure supplement 4. Ig fusion proteins of CTLA4, PD-1, VISTA, CD226 and TIGIT do not abolish the suppression of CRIg-Ig in T cells.
DOI: https://doi.org/10.7554/eLife.29540.010
Yuan et al. eLife 2017;6:e29540. DOI: https://doi.org/10.7554/eLife.29540 6 of 29
Research article Immunology
???
??
??
??
???
??
???
? ??
???
??
?
??? ?????????
? ??? ??? ???
???? ???????
???????
???????
????
??
??
?
? ??? ??? ???
????????????????
??????
??
??
?
????
??
??
?
???
?????????
????????
????????
??????? ????????
???????????????? ??????????
???????? ?????? ????
?? ???
??
??
??
?? ??
?? ???
??
??
??
?? ?
?? ???
??
??
??
?? ????
????? ???????? ????
???????
?????????
Figure 3. CRIg promotes iTreg generation in vitro. (A) (left) Representative FACS plots depicting the generation of iTreg cells in the presence of CRIg-
Ig, or control Ig, under various concentrations of TGF-b. (right) Statistics of multiple experiments. (B) Tconv cells were cultured in the condition of anti-
CD3/CD28 and IL-2, anti-TGF-b neutralizing antibody (clone 1D11) and either control Ig, or CRIg-Ig. (C) Total splenocytes from 8-week-old NOD/
BDC2.5/Thy1.1 mice were labeled with CTV and cultured with BDC2.5 mimotope (100 ng/ml) for 3 days. The generation of Treg cells were analyzed by
Figure 3 continued on next page
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generation of iTreg cells (Figure 3A). CRIg-mediated enhancement of iTreg generation was more
profound when TGF-b concentration was relatively low (e.g., there was a more than two-fold
increase of iTreg induction by CRIg-Ig with 0.2 ng/ml TGF-b) (Figure 3A). To assess whether CRIg-Ig
alone could induce the conversion of Tconv cells into iTreg cells, an anti-TGF-b neutralizing mAb
(clone 1D11) (ref. [Chang et al., 2015]) was added to eliminate any trace-amount of TGF-b in the cul-
ture medium. In the absence of TGF-b, CRIg-Ig alone did not induce the generation of iTreg cells
(Figure 3B). Treg cells can be converted from Tconv cells under the conditions where antigens (Ag)
are encountered in the absence of optimal costimulation (Kretschmer et al., 2005; Verginis et al.,
2008). To examine whether CRIg has an effect on Ag-induced Treg generation, we cultured total
splenocytes from NOD/BDC2.5 mice with the cognate Ag mimotopes (Haskins et al., 1988;
Katz et al., 1993). Compared with control Ig, CRIg-Ig induced a 2-fold increase of Treg generation
(Figure 3C), suggesting a role of CRIg in promoting Ag-stimulated Treg generation. We next evalu-
ated whether CRIg+ macrophages can promote iTreg generation. Using an in vitro Ag-stimulated
iTreg generation condition, we found that even though CRIg- macrophages can modestly promote
Ag-induced iTreg generation, this effect was significantly elevated by CRIg+ macrophages
(Figure 3D). Therefore, CRIg promotes iTreg generation induced by either TGF-b, or Ag.
To evaluate the in vivo effect of CRIg in peripherally Treg (pTreg) generation, we transferred
highly purified CD4+ Foxp3(GFP)- Tconv cells isolated from NOD/BDC2.5/Thy1.1+/Foxp3GFP mice
into 4-week-old NOD mice. We found that a 2-week in vivo CRIg-Ig treatment preferentially
enhanced pTreg development in pancreatic islets, not pancreas- draining or non-draining lymph
nodes (Figure 3E). Conversely, we transferred purified BDC2.5+ CD4+ Foxp3(GFP)- Tconv cells into
either NOD or NOD/CRIg KO mice. The generation of Treg cells was compromised in the absence
of CRIg (Figure 3F). Of note, this reduction only occurred in the pancreas, not in pancreas-draining
or non-draining lymph nodes, suggesting a local microenvironment-specific role of CRIg in regulat-
ing pTreg generation. Consistent with the role of CRIg in affecting Treg cells at tissue sites, we
found that Helios- peripherally-induced Treg (pTreg) (Shevach and Thornton, 2014) cells were pref-
erentially reduced in pancreas and colon of NOD/CRIg KO mice, compared with wildtype controls
(Figure 3G). In contrast, since there was no CRIg expression in lung macrophages (Figure 1—figure
supplement 1), pTreg cells in the lung were not affected by CRIg deficiency.
We next investigated what pathways were affected in CRIg-promoted iTreg cells. It has been
demonstrated that mTOR pathway kinase AKT has a negative impact on Treg cell development
(Haxhinasto et al., 2008). We asked whether CRIg affected AKT activity during iTreg differentiation.
Under iTreg induction condition, plate-bound CRIg-Ig more potently suppressed the phosphoryla-
tion of AKT (Figure 3H). Similarly, the phosphorylation of S6 ribosomal protein, a downstream target
of mTOR pathway was also more significantly suppressed by CRIg-Ig (Figure 3I). However, CRIg-Ig
did not enhance TGF-b induced phosphorylation of Smad2/3 (Figure 3—figure supplement 1).
Thus, CRIg-Ig potentiates iTreg generation via suppressing AKT-MTOR pathway.
Figure 3 continued
intracellular Foxp3 staining. (D) iTreg generation in vitro as in (C) with the inclusion of CRIg+ or CRIg- macrophages, sorted from peritoneal cavity. (E)
Purified CD4+Foxp3 (GFP)- T cells from NOD/BDC2.5/Foxp3GFP/Thy1.1 mice were transferred into 4-week-old NOD mice, followed by i.p. injection of
CRIg-Ig, or control Ig every other day for 2 weeks. (F) Purified CD4+Foxp3 (GFP)- T cells from NOD/BDC2.5/Foxp3GFP/Th1.1 mice were transferred into
4-week-old NOD or NOD/CRIg KO mice. The generation of Foxp3(GFP)+ cells in pancreatic islets, panLNs and inguinal LNs(ILNs) was analyzed 2 weeks
after the transfer. (G) Flow cytometric analyses of Helios- Treg cells from pancreas, colon and lung of NOD/CRIgKO and wildtype controls. (H, I)
Purified CD4+ Foxp3(GFP)- T cells were cultured with either control Ig or CRIg-Ig for 18 hr and analyzed for the phosphorylation of AKT (H) and
ribosomal protein S6 (I). Dotted line, control Ig; solid line, CRIg-Ig. Data are representative of five (A), three (B–I) experiments. Student’s t-test was used.
n.s., non-significant. *p<0.05; ***p<0.001; ****p<0.0001. Ctl, control; KO, CRIg knockout.
DOI: https://doi.org/10.7554/eLife.29540.011
The following figure supplements are available for figure 3:
Figure supplement 1. CRIg-Ig does not enhance TGF-b induced phosphorylation of Smad2/3.
DOI: https://doi.org/10.7554/eLife.29540.012
Figure supplement 2. Experimental design and FACS profiles of in vivo pTreg generation promoted by CRIg-Ig.
DOI: https://doi.org/10.7554/eLife.29540.013
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CRIg stabilizes Foxp3 expression in iTreg cells
iTreg cells lose their expression of Foxp3 when they are restimulated with TCR signaling
(Feng et al., 2014; Yue et al., 2016). We asked whether CRIg-Ig affected the stability of iTreg cells.
CD4+ Foxp3(GFP)- cells from NOD/Foxp3GFP mice were FACS purified and cultured under the iTreg
differentiation condition. After 24 hr, about 20% of cultured cells were Foxp3(GFP)+. We sorted
these GFP+ cells and recultured them with anti-CD3/CD28 and IL-2, in the presence of either CRIg-
Ig, or control Ig (Figure 4A). An anti-TGF-b neutralizing antibody (clone 1D11) was added to elimi-
nate the trace amount of TGF-b in the culture medium. After 3 days, about 50% of control iTreg cells
lost their expression of Foxp3 (Figure 4B). In contrast, in the presence of plate-bound CRIg-Ig, a sig-
nificantly higher fraction of iTreg cells retained Foxp3 (Figure 4B). The loss of Foxp3 in restimulated
iTreg cells was exacerbated over the course of cell dividing. This instability of Foxp3 expression was
repressed by CRIg-Ig, especially when the cells underwent multiple divisions (Figure 4C). Moreover,
the expression level of Foxp3 protein on a per cell basis was also higher in restimulated iTreg cells in
the presence of CRIg-Ig, compared to that in control group (Figure 4D). Notably, this Treg-stabiliz-
ing effect of CRIg is TGF-b independent, because we have added an anti-TGF-b neutralizing mAb to
eliminate any trace amount of TGF-b. Thus, CRIg retains the expression of Foxp3 in Treg cells. In line
with a Treg–stabilizing effect, CRIg preconditioned iTreg cells exhibited an enhanced suppressive
capacity in an in vitro Treg suppression assay (Figure 4—figure supplement 1).
CRIg-Ig stabilizes iTreg cells by enhancing their responsiveness to IL-2
We next attempted to identify the mechanisms by which CRIg stabilized Foxp3 in Treg cells.
Demethylation of CpG sites in the second CNS region (CNS2) of Foxp3 is critical for Treg stability
(Floess et al., 2007; Zheng et al., 2010). We asked whether CRIg-Ig had an effect on Foxp3 CpG
demethylation. We used bisulfite colony sequencing of PCR products of CNS2 regions
(Kalekar et al., 2016). To this end, iTreg cells were generated, sorted as GFP(Foxp3)+ cells and
recultured with anti-CD3/CD28 and IL-2, in the presence of CRIg-Ig, or control Ig. After 3 days,
genomic DNAs from re-sorted GFP+ cells were extracted and processed for bisulfite sequencing of
the Foxp3 CNS2 region. As expected, CpG sites in Foxp3 CNS2 region of control iTreg cells were
highly methylated (Figure 4E). A similar profile of CpG methylation was observed in CRIg iTreg cells
(Figure 4E). These data suggest that CRIg-promoted iTreg stability is not a consequence of demeth-
ylation in Foxp3 CNS2 region.
IL-2 signaling is critical for Treg stability, by retaining the expression of Foxp3 (refs [De´pis et al.,
2016; Chen et al., 2011]). We asked whether iTreg cells, when restimulated in the presence of
CRIg-Ig, were more responsive to limited amount of IL-2. In this regard, TGF-b induced iTreg cells
were sorted and restimulated with anti-CD3/CD28, in the presence of CRIg-Ig or control Ig, with var-
ious doses of IL-2. In control iTreg cells restimulated with anti-CD3/CD28, increased concentrations
of IL-2 did not prevent the loss of Foxp3 in these cells. In contrast, the presence of CRIg-Ig resulted
in a significantly higher fraction of restimulated iTreg cells retaining their expression of Foxp3, in the
presence of IL-2 (Figure 4F). CRIg induced iTreg cells expressed a higher level of IL-2Rb
(Figure 4G), suggesting an enhanced responsiveness of these cells to IL-2. Signal transducer and
activator of transcription 5 (STAT5) is key downstream target of IL-2 signaling (Burchill et al., 2007;
Yu et al., 2009). IL-2-induced STAT5 phosphorylation in iTreg cells was significantly enhanced by
CRIg-Ig (Figure 4H). Therefore, CRIg retains Foxp3 expression in iTreg cells by enhancing their
responsiveness to IL-2.
CRIg stabilizes Treg cells in vivo in lymphopenic condition
Treg cells lose Foxp3 expression when they are transferred into lymphopenic mice (Duarte et al.,
2009; Bailey-Bucktrout and Bluestone, 2011). Using neonatal NOD mice as lymphopenic hosts, we
analyzed whether CRIg-preconditioned iTreg cells were more stable in vivo. CD4+ Foxp3(GFP)- cells
from NOD/Foxp3GFP/Thy1.1+ mice, or NOD/Foxp3GFP/Thy1.1+ Thy1.2+ mice were sorted and differ-
entiated into iTreg cells by either TGF-b (control iTreg), or TGF-b plus CRIg-Ig (CRIg iTreg). Both
control iTreg cells and CRIg iTreg cells were sorted as GFP+ cells and mixed at 1:1 ratio before
transferring into neonatal NOD mice (Thy1.2+) (Figure 5A). One week later, transferred iTreg cells
from both spleen and pancreatic islets were analyzed. Control and CRIg iTreg cells exhibited similar
degrees of engraftments (Figure 5B,C), suggesting that preconditioning with CRIg did not affect
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Figure 4. CRIg stabilizes Foxp3 expression in TGF b induced iTreg cells. (A) Experimental setting. (B) The fraction of Foxp3 positivity and the division
of recultured iTreg cells. Left, representative FACS plots; right, the statistics of multiple experiments (n = 7). (C) The percentage of cells retaining Foxp3
expression in each cell division. (D) The MFI of Foxp3 protein in each generation of cell division. (E) The methylation percentage at each CpG motif in
Foxp3 CNS2 of control iTreg (grey bars), or CRIg iTreg cells (black bars) (see Figure 4—source data 1) (F) In vitro differentiated iTreg cells were
Figure 4 continued on next page
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homeostatic survival and expansion of these adoptively transferred cells. However, iTreg cells gener-
ated in the presence of CRIg-Ig showed an enhanced stability under lymphopenic condition. In
spleen, a significantly higher fraction of transferred CRIg-iTreg cells maintained their expression of
Foxp3 (Figure 5B). Although CRIg (plate-bound) was present during the in vitro generation of iTreg
cells, it was dissociated from these cells after adoptive transfer. Since there was no CRIg expression
in spleen (Helmy et al., 2006; Vogt et al., 2006) (and our unpublished data), it thus suggests that a
continuous cell-cell contact between Treg cells and CRIg+ TRMs is not necessarily needed for retain-
ing Foxp3 expression. The instability of adoptively transferred iTreg cells was more profoundly exac-
erbated in pancreatic islets, as expected. However, preconditioning with CRIg before the adoptive
transfer retained a significantly higher percentage of Foxp3 expression (Figure 5C). Thus, iTreg cells
generated by TGF-b plus CRIg-Ig are more stable in vivo.
In vivo CRIg modulation corrects immune dysregulation in an
autoimmune condition
Immune dysregulation characterized by loss-of balance between regulatory and effector immune
cells is key for the pathogenesis of many autoimmune diseases, including T1D (Bluestone et al.,
2010; Anderson and Bluestone, 2005). Our data suggested that CRIg may possess a role in modu-
lating the dysregulated immune responses. We assessed this possibility in NOD mice, the primary
animal models for human T1D (Anderson and Bluestone, 2005). Our in vitro studies revealed that
cross-linking CRIg with an anti-CRIg mAb (e.g., clone 17C9) significantly enhanced TGF-b-induced
iTreg generation (Figure 6—figure supplement 1). In vivo analyses revealed that serum half-life of
CRIg-Ig was significantly prolonged when an anti-CRIg mAb (clone 17C9) was administrated simulta-
neously with CRIg-Ig (Figure 6—figure supplement 2). Moreover, anti-CRIg mAb alone did not alter
the compositions of T cells in vivo, including Treg cells (Figure 6—figure supplement 3A). There-
fore, we used CRIg-Ig/anti-CRIg mAb complex to treat NOD mice. Ten-week old pre-diabetic NOD
mice were treated with CRIg-Ig/anti-CRIg complex or control Ig for two weeks. Immune cells isolated
from the spleen, pancreatic draining lymph nodes (panLNs) and pancreatic islets were analyzed. We
first focused on analyzing whether in vivo CRIg modulation altered the balance between regulatory
and effector T cells in NOD mice. Of note, the ratios between Treg cells and CD4+ Tconv cells in
pancreatic islets were significantly increased in CRIg-Ig/anti-CRIg complex treated mice, with about
50% of the mice exhibited a robust response (Figure 6A). Similar results were observed in the ratios
between Treg and CD8+ T cells (Figure 6A). Of note, such an effect was only seen at tissue sites
(pancreatic islets), not in lymphoid organs, such as panLNs (Figure 6B), or spleen (Figure 6—figure
supplement 3B). Thus, in vivo CRIg modulation rebalances immune compositions in situ under an
autoimmune condition.
In addition to altering the ratios between regulatory and effector T cells, we asked whether CRIg
affected the functional properties of T cells. Interestingly, in vivo CRIg modulation increased the pro-
portion of Helios- Treg cells (Figure 6C), indicating an enhanced generation of pTreg cells
(Thornton et al., 2010). This is consistent with the results of CRIg-Ig promoted in vivo pTreg genera-
tion from adoptively transferred Tconv cells (Figure 3E). Elevated expression of ICOS is a marker for
effector Treg cells (Smigiel et al., 2014). We found that a significantly increased proportion of islet
Figure 4 continued
restimulated with anti-CD3/CD28, and various concentrations of IL-2, in the presence of CRIg-Ig, or control Ig. The fraction of cells retaining Foxp3
expression was analyzed after 3 days. (G) The expression of IL-2Rb in control and CRIg iTreg cells after 3 days of culture. (H) The phosphorylation of
STAT5 in control and CRIg iTreg cells. Data are representative of seven (B–D), two (E), and three (F–H) experiments, respectively. Student’s t-test was
used. *p<0.05; **p<0.01; ***p<0.001.
DOI: https://doi.org/10.7554/eLife.29540.014
The following source data and figure supplement are available for figure 4:
Source data 1. The methylation percentage at each CpG motif in Foxp3 CNS2 of control iTreg cells, CRIg iTreg cells and ex vivo Treg cells (associated
with Figure 4E).
DOI: https://doi.org/10.7554/eLife.29540.016
Figure supplement 1. CRIg enhances iTreg suppressive function.
DOI: https://doi.org/10.7554/eLife.29540.015
Yuan et al. eLife 2017;6:e29540. DOI: https://doi.org/10.7554/eLife.29540 11 of 29
Research article Immunology
?????????????
???????? ???? ?????????
???????????
????? ???????
????????????
?????????
????????
??
??????????????
??????? ???????????
????????????????
?????????????
??????????????
?????????????????
?????? ????????
?????
??????
??
??
??
????????
???????
??????? ????????
??
??
??
?? ***
???
??
??
?
??
??
?
?????
??????? ????????
??
??
?? ***
??????
??
??
??
????????
???????
???
??
??
?
???
??
??
?
???????????????
????? ???
????? ?????
????
??
???
???????
??????????????????
????????
Figure 5. CRIg stabilizes adoptively transferred iTreg cells in vivo. (A) Experimental design. (B, C) One week later, the transferred cells were isolated
from spleen (B) and pancreatic islets (C) and were analyzed for the expression of Foxp3. Control iTreg cells, Thy1.1+ Thy1.2+; CRIg iTreg cells,
Thy1.1+ Thy1.2-. Data are representative of two independent experiments with 9 mice in total. Student’s t-test was used. ***p<0.001.
DOI: https://doi.org/10.7554/eLife.29540.017
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Treg cells from CRIg-Ig/anti-CRIg treated mice were ICOShi (Figure 6D). Thus, in vivo CRIg modula-
tion increases pTreg development and functional maturation at tissue sites.
As a consequence of CRIg on helper T (Th) cell differentiation, we observed a significantly
reduced IFN-g production in CD4+ Tconv cells from pancreatic islets (Figure 6E). However unexpect-
edly, IL-17+ T (Th17) cell differentiation was significantly increased in pancreatic islets of CRIg-Ig/
anti-CRIg complex treated mice (Figure 6F). The role for Th17 cells in T1D has been controversial,
either diabetogenic (Emamaullee et al., 2009; Gao et al., 2010) or protective (Tse et al., 2010;
Nikoopour et al., 2010). One model of Th17’s role in T1D is that these cells convert to diabetogenic
IFN-g+ Th1 cells in vivo (Martin-Orozco et al., 2009; Bending et al., 2009). Because we have previ-
ously found that the onset of diabetes was suppressed in CRIg-Ig treated NOD mice (Fu et al.,
2012), it thus can be speculated that these accumulated Th17 cells in pancreatic islets are not
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Figure 6. CRIg restores immune tolerance in pancreatic islets of NOD mice. The ratios of Treg/Tconv cells, and Treg/CD8+ T cells in the pancreas (A)
and panLNs (B) of control (n = 14) and CRIg-Ig/anti-CRIg treated mice (n = 16). The expression of Helios (C) and ICOS (D) in Treg cells from pancreatic
islets of control (n = 7 in C, n=3 in D) and CRIg-Ig/anti-CRIg (labeled as CRIg/mAb in the figure panels, n = 8 in C, n=4 in D) treated mice. The
production of IFN-g (E) and IL-17 (F) in CD4+ Tconv cells from pancreatic islets in control Ig (n = 5) and CRIg-Ig/anti-CRIg (n = 6) treated mice. Data are
representative of six (A, B), three (C), and two (D–F) experiments, respectively. Student’s t-test was used. n.s., non-significant; *p<0.05; **p<0.01;
***p<0.001.
DOI: https://doi.org/10.7554/eLife.29540.018
The following figure supplements are available for figure 6:
Figure supplement 1. Cross-linking CRIg with anti-CRIg mAb enhances iTreg generation.
DOI: https://doi.org/10.7554/eLife.29540.019
Figure supplement 2. Anti-CRIg mAb prolongs in vivo half-life of CRIg-Ig.
DOI: https://doi.org/10.7554/eLife.29540.020
Figure supplement 3. In vivo modulation of CRIg in NOD mice.
DOI: https://doi.org/10.7554/eLife.29540.021
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diabetogenic. The elevated proportion of IL-17+ T cells in pancreatic islets of CRIg-treated NOD
mice may be due to a blocked conversion from Th17 into Th1 cells.
Thus, in vivo CRIg modulation corrects immune dysregulation occurred in autoimmune conditions.
Such an outcome is achieved through a dual effect of CRIg: the suppression of pathogenic Th1 cells
and the promotion of Treg cell differentiation and function. The diabetogenicity of effector T cells
can be further dampened by elevated Treg abundance and function. Overall, CRIg-mediated immu-
nomodulation diverts autoimmunity towards immunological tolerance.
The expression of CRIg in TRMs is influenced postnatally by microbial
signals
The above findings support a role of CRIg as a tissue environment-specific checkpoint molecule for
immunological homeostasis. The dearth of CRIg expression in TRMs is tightly correlated with exacer-
bated tissue inflammation (Figure 1). Therefore, it is worth investigating what factors and signals
regulate the expression of CRIg in TRMs. CRIg is abundantly expressed in a number of organs/tis-
sues, including liver Kupffer cells of adult mice (Figure 7A) (Helmy et al., 2006). However, in con-
trast, CRIg was almost completely absent in the liver from neonatal (day one post birth) mice,
though F4/80+ Kupffer cells were readily detected (Figure 7A). We confirmed the absence of CRIg
expression in macrophages from other tissues, including the pancreas in neonatal mice (Figure 7B).
Therefore, CRIg is not constitutively expressed in macrophages, rather, is contingent upon extrinsic
signals arisen postnatally. We then asked when the expression of CRIg was induced postnatally. For
this, we tracked the expression of CRIg in peritoneal large TRMs (F4/80hi) longitudinally in both
NOD and B6 strains (Figure 7C and Figure 7—figure supplement 1A). Clearly, there was a sharp
increase of CRIg expression in macrophages around the time of weaning, a time-point when mice
were exposed to environmental cues (Laukens et al., 2016). The colonization of gut microbiota at
early age, especially around the time of weaning is critical for the postnatal development of immune
system. To evaluate whether the expression of CRIg was influenced by gut microbiota, we treated
adult B6 mice with a combination of four antibiotics (vancomycin, metronidazole, neomycin and
ampicillin, VMNA) (Sefik et al., 2015) for one week in drinking water. We analyzed the expression of
CRIg in various tissues, including pancreas, colon and peritoneal cavity. Though the fraction of CRIg+
TRMs in peritoneal cavity was not affected by antibiotic treatment, in contrast, at tissue sites (colon
and pancreas), the fractions of CRIg+ TRMs were significantly decreased (Figure 7D–F). Of note, at
all examined locations, antibiotic treatment significantly diminished CRIg expression on a per cell
basis in macrophages (Figure 7D–F). These data suggest that CRIg expression in TRMs is induced
postnatally by microbial signals.
Retinoic acid signaling retains CRIg expression in macrophages in vitro
and in vivo.
We have found that TRMs (both CRIg+ and CRIg- subsets) abundantly express retinoic acid (RA)
receptors (RAR) (Figure 7G), suggesting that these cells are able to respond to RA. Therefore, we
tested whether RA affected CRIg expression. We isolated CRIg+ macrophages from peritoneal cavity
of 7-week-old B6 mice and cultured them in the presence, or absence of all-trans RA (ATRA), the
active form of RA. In the absence of ATRA, the expression of CRIg decreased (reflected by a lower
MFI of CRIg) after 3-day culture. In contrast, ATRA retained the expression of CRIg, to a level com-
parable to that in freshly isolated CRIg+ macrophages (Figure 7H). Interestingly, ATRA also
increased CRIg expression in isolated CRIg- macrophages (Figure 7—figure supplement 1B), sug-
gesting that RA signaling may be involved in inducing CRIg expression in macrophages. Might RA
affect CRIg expression in vivo? To test this, we treated 7-week-old B6 mice with an inverse pan-RA
agonist BMS 493 (ref [Chazaud et al., 2003]) to block RA signaling. Compared with control vehicle-
treated mice, BMS 493 significantly reduced CRIg expression in peritoneal, but not pancreatic F4/
80hi TRMs (Figure 7I,J). Consistently, BMS 493 treatment also reduced the expression of CRIg in
peritoneal macrophages in an adoptive transfer setting, where donor CRIg+ macrophages were puri-
fied from congenically-labeled mice (Figure 7—figure supplement 1C). Collectively, these data sug-
gest that RA signaling is involved in regulating CRIg expression in TRMs in a tissue-specific manner.
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Figure 7. The expression of CRIg in TRMs is influenced by environmental factors. (A) The expression of CRIg in liver Kupffer cells of adult (7
weeks of age) and neonatal (day one post birth) B6 mice. Green, F4/80; Red, CRIg. (B) The expression of CRIg in pancreatic islets of adult (10
weeks of age) and neonatal (day seven post birth) NOD mice. Green, F4/80; Red, CRIg. (C) Longitudinal analysis of CRIg expression in peritoneal F4/
80hi TRMs of NOD mice. Red: females; Blue, males. Dotted green line depicts the time of weaning. (D–F) The percentages and the MFI of CRIg
Figure 7 continued on next page
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Discussion
How adaptive immunity at tissue sites is regulated by local microenvironment remains poorly under-
stood. We here define a new model of regulating T cell activities by tissue resident cells. In this
model, TRMs sense environmental cues and express CRIg. Through the function of CRIg, tissue-spe-
cific autoimmunity is suppressed and immune tolerance is reinforced. Multiple mechanisms are
involved in this model to promote immune tolerance. First, CRIg+ TRMs form a barrier protecting
pancreatic islets from succumbing to destructive insulitis. Second, CRIg preferentially suppresses
effector T cell proliferation. Third, CRIg promotes the differentiation and stability of Treg cells.
CRIg+ TRM mediated protection provides one explanation why not all islets are equally des-
tructed during T1D development. In animal models and arguably in human patients of T1D, islet
autoimmunity (insulitis) is universally present. However, not all insulitis proceeds to become diabetic
(Fu et al., 2012; Andre´ et al., 1996; Poirot et al., 2004). Even in genetically identical monozygotic
twins, the concordance of T1D incidence is only about 40–50%. It is still elusive what determines the
risk of one individual to become diabetic. Moreover, not all islets are equally destroyed and there
exist intact islets even in longstanding diabetic patients (Bluestone et al., 2010). It is unclear why
some islets are free from immune infiltration while the others are not. CRIg+ TRMs specifically local-
ize in the capsular area of an islet. The dearth of CRIg expression in these TRMs is correlated with
the aggressiveness of insulitis in each individual islet. In line with this, insulitis is markedly exacer-
bated in NOD mice with CRIg-null mutation.
Several aspects of T cell activities can be modulated by CRIg. For each of them, our data also
provide critical mechanistic insights. First, CRIg suppresses T cell proliferation by attenuating the
activation of multiple TCR signaling cascades, including the most proximal signaling complex, the
ERK-MAPK pathway and the AKT-MTOR pathway. The preferential suppression of effector T cells by
CRIg is likely due to a higher level of the expression of a putative CRIg receptor in effector T cells
than that in Treg cells. Our binding assays suggest that the receptor for CRIg is only transiently
induced during early activation phase in T cells. Using competition assays, we have excluded a num-
ber of known coinhibitory molecules of immunoglobulin family as a potential receptor for CRIg.
Other approaches including biochemical assays and protein interaction arrays will be employed to
identify the receptor for CRIg. Second, reminiscent of the role of PD-L1 (refs [Francisco et al., 2009;
Wang et al., 2008]), CRIg can also promote TGF-b induced Treg differentiation. CRIg does not
directly enhance TGF-b signaling, instead, it robustly suppresses AKT signaling under iTreg induction
condition, thus potentiating the differentiation of iTreg cells. Beyond promoting iTreg differentia-
tion, another key finding is that CRIg increases the stability of Treg cells. This Treg-stabilizing effect
of CRIg is not attributed to epigenetic modification of Foxp3 promoter, instead, CRIg makes Treg
cells more sensitive to IL-2 by increasing the expression of IL-2Rb and the phosphorylation of STAT5.
Moreover, our data suggest that Treg cells do not need continuous cell-cell contact with CRIg+
TRMs to maintain Foxp3 expression.
Adoptive transfer of Treg cells is a promising strategy to induce immune tolerance in the treat-
ment of human autoimmune diseases and organ transplantations (Tang and Bluestone, 2013). How-
ever, variable stabilities of in vitro generated iTreg cells hinder this therapeutic option. We propose
that CRIg may become a potential candidate to overcome the barrier of instability in Treg-based
Figure 7 continued
expression in TRMs from peritoneal cavity (D), pancreatic islets (E) and colon (F) of control and antibiotics treated B6 mice, respectively. (G) The
expression of retinoic acid receptors in CRIg+ and CRIg- TRMs isolated from peritoneal cavity of 7 weeks old B6 mice. (H) CRIg+ macrophages were
isolated from peritoneal cavity and cultured in vitro in the presence or absence of ATRA. The expression of CRIg in cultured cells were analyzed 3 days
later. blue line, no ATRA; red line, with ATRA. (I, J) In vivo treatment of 7 weeks old B6 mice with an inverse pan-RA agonist BMS 493 to block RA
signaling. The expression of CRIg in TRMs from peritoneal cavity (I) and pancreatic islets (J) was analyzed 3 days later. Data are representative of three
(A, B, D–J), and more than five (C) experiments, respectively. Student’s t-test was used. n.s., non-significant; *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001. w/o, without.
DOI: https://doi.org/10.7554/eLife.29540.022
The following figure supplement is available for figure 7:
Figure supplement 1. RA signaling is involved in CRIg expression in TRMs.
DOI: https://doi.org/10.7554/eLife.29540.023
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therapies. Correlated with the enhanced stability of CRIg iTreg cells, these cells are also more sup-
pressive in a T cell proliferation assay.
CRIg has also been reported as a complement receptor (Helmy et al., 2006). However, our data
reveal that the effects of CRIg in T cells can be exerted in a complement-independent manner. This
suggests that complement components are not necessarily involved in CRIg-mediated suppression
of effector T cells and differentiation of Treg cells.
CRIg emerges as a molecular link between environmental cues and adaptive immunity in control-
ling excessive tissue inflammation. The expression of CRIg in macrophages is dampened by inflam-
matory signals, such as lipopolysaccharide (Vogt et al., 2006). Loss of abundancy of CRIg+
macrophages is associated with exacerbated tissue inflammation in multiple autoimmune conditions
(Vogt et al., 2006; Fu et al., 2012). Therefore, identifying what signals induce or suppress the
expression of CRIg in TRMs is essential for better understanding how TRMs sense environmental sig-
nals and in turn orchestrate the activities of T cells. We find that CRIg expression in TRMs is induced
postnatally and the abundance of CRIg+ TRMs sharply increases around weaning, a time window
allowing postnatal colonization of gut microbiota in mice (Laukens et al., 2016). The connection
between gut microbiome and CRIg is evident from our studies showing that antibiotic treatment
diminishes CRIg expression in TRMs at various locations, including colon, pancreas and peritoneal
cavity. A recent study has demonstrated that antibiotic-mediated gut dysbiosis accelerated the
development of T1D in mice (Livanos et al., 2016). The dampened expression of CRIg in pancreatic
TRMs under dysbiotic conditions could be one plausible mechanism. Thus, environmental factors
(most likely microbial signals and metabolites) instruct TRMs to express CRIg, which functions as an
immune checkpoint molecule to regulate tissue T cell activities.
We found CRIg+ cells in human pancreas, suggesting a potential role of CRIg in human T1D.
CRIg+ TRMs are also abundantly present in other gastrointestinal organs, including liver and intes-
tines in both mice and humans (Helmy et al., 2006). It thus can be speculated that CRIg may
also play a role in maintaining immunological homeostasis in these tissues.
Materials and methods
Key resources table
Reagent type
(species)
or resources Designation Source or reference Identifiers Additional information
strain,
strain background
(Mus musculus)
C57BL/6 (B6) mice The Jackson
Laboratory
RRID:
IMSR_JAX:000664
strain,
strain background
(Mus musculus)
NOD mice Mathis-Benoist
laboratory
RRID:
IMSR_JAX:001976
strain,
strain background
(Mus musculus)
NOD/Foxp3GFP mice The Jackson
Laboratory
RRID:
IMSR_JAX:025097
strain,
strain background
(Mus musculus)
B6/CD45.1 mice Dr. Li-Fan Lu, UCSD RRID:
IMSR_JAX:002014
strain,
strain background
(Mus musculus)
NOD/BDC2.5
/Thy1.1 mice
Mathis-Benoist
laboratory
strain,
strain background
(Mus musculus)
NOD/BDC2.5
/Foxp3GFP
/Thy1.1 mice
this paper NOD/BDC2.5/Foxp3GFP/
Thy1.1 mice were
generated by crossing
NOD/BDC2.5/Thy1.1
mice to NOD/
Foxp3GFP mice.
Continued on next page
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Continued
Reagent type
(species)
or resources Designation Source or reference Identifiers Additional information
strain,
strain background
(Mus musculus)
NOD/BDC2.5
/Foxp3GFP
/Thy1.1/Thy1.2 mice
this paper NOD/BDC2.5/Foxp3GFP/
Thy1.1/Thy1.2
mice were
generated by crossing
NOD/BDC2.5/Thy1.1
mice to NOD/Foxp3GFP mice.
strain,
strain background
(Mus musculus)
B6/CRIg KO mice Genentech PMID: 16530040
strain,
strain background
(Mus musculus)
NOD/CRIg KO mice this paper NOD/CRIg-/- mice were
generated
by crossing B6/CRIg-/-
mice onto a NOD
background for more
than 10 generations.
biological sample
(Mus musculus)
pancreas other prepared from NOD mice
biological sample
(Mus musculus)
colon lamina
propria
other prepared from
NOD orB6 mice
biological sample
(Mus musculus)
peritoneal
cavity cells
other prepared from
NOD or B6 mice
biological sample
(Mus musculus)
lung other prepared from
NOD or B6 mice
biological sample
(Mus musculus)
liver other prepared from
NOD or B6 mice
biological sample
(Mus musculus)
serum other prepared from
NOD mice
biological sample
(Mus musculus)
panLNs other pancreatic
draining lymph
nodes from NOD mice
biological sample
(Mus musculus)
ILNs other Inguinal
lymph nodes from
NOD or B6 mice
biological sample
(Mus musculus)
spleen other prepared from
NOD or B6 mice
biological sample
(Mus musculus)
macrophages other defined as F4/80+
or F4/80+ CD11b+ cells
biological sample
(Mus musculus)
Treg cells other defined as CD4+
Foxp3+ T cells
biological sample
(Mus musculus)
Tconv cells other defined as CD4+
Foxp3- T cells
antibody Ultra-LEAF Purified
anti-mouse CD3e
(Armenian hamster
monoclonal)
BioLegend RRID:AB_11149115 clone: 145–2C11
antibody Ultra-LEAF Purified
anti-mouse CD28
(Syrian hamster
monoclonal)
BioLegend RRID:AB_11150408 clone: 37.51
antibody anti-gp120
(mouse monoclonal)
Genentech control Ig in this paper
PMID: 16530040
antibody anti-CRIg Genentech clone: 14G8 (mouse monoclonal;
PMID: 19017980);
clone: 17C9 (rat monoclonal;
PMID: 16530040)
Continued on next page
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Continued
Reagent type
(species)
or resources Designation Source or reference Identifiers Additional information
antibody anti-TGF-b 1, 2, 3
(mouse monoclonal)
R and D Systems RRID:AB_357931 clone: 1D11
antibody anti-CD16/CD32
(rat SD
monoclonal)
BD Biosciences RRID:AB_394656 clone: 2.4G2
antibody anti-CRIg
(mouse monoclonal)
this paper Biotinylated anti-CRIg
(clone: 14G8) prepared
by our laboratory
antibody anti-CD45
(rat monoclonal)
BioLegend RRID:AB_312981 clone: 30-F11
antibody anti-CD45.1
(mouse monoclonal)
BioLegend RRID:AB_893346 clone: A20
antibody anti-CD45.2
(mouse monoclonal)
BioLegend RRID:AB_389211 clone: 104
antibody anti-TCRb
(Armenian hamster
monoclonal)
BioLegend RRID:AB_493344 clone: H57-597
antibody anti-CD4
(rat monoclonal)
BioLegend RRID:AB_312719;
RRID:AB_312713;
RRID:AB_312715
clone: RM4-5
antibody anti-CD8a
(rat monoclonal)
BioLegend RRID:AB_312747;
RRID:AB_312761
clone: 53–6.7
antibody anti-Thy1.1
(mouse monoclonal)
BioLegend RRID:AB_961437 clone: OX-7
antibody anti-Thy1.2
(rat monoclonal)
BioLegend RRID:AB_492888 clone: 30-H12
antibody anti-Helios
(Armenian hamster
monoclonal)
BioLegend RRID:AB_10660749 clone: 22F6
antibody anti-ICOS
(rat monoclonal)
ebioscience RRID:AB_2573563 clone: 7E.17G9
antibody anti-CD122
(rat monoclonal)
BioLegend RRID:AB_313226 clone: 5H4
antibody anti-CD25
(rat monoclonal)
BioLegend RRID:AB_312857;
RRID:AB_312865
clone: PC61
antibody anti-CD69
(Armenian hamster
monoclonal)
BioLegend RRID:AB_2260065 clone: H1.2F3
antibody anti-CDF4/80
(rat monoclonal)
BioLegend RRID:AB_893481 clone: BM8
antibody anti-CD11b
(rat monoclonal)
BioLegend RRID:AB_312791;
RRID:AB_755986
clone: M1/70
antibody anti-CD11c
(Armenian hamster
monoclonal)
BioLegend RRID:AB_313777 clone: N418
antibody anti-CD19
(rat monoclonal)
BioLegend RRID:AB_313643 clone: 6D5
antibody anti-NKp46
(rat monoclonal)
BioLegend RRID:AB_2235755 clone: 29A1.4
antibody anti-IL-17
(rat monoclonal)
BioLegend RRID:AB_536018 clone: TC11-18H10.1
antibody anti-IFN-g
(rat monoclonal)
BioLegend RRID:AB_315402 clone: XMG1.2
Continued on next page
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Continued
Reagent type
(species)
or resources Designation Source or reference Identifiers Additional information
antibody anti-Foxp3
(rat monoclonal)
ebioscience RRID:AB_1518812 clone: FJK-16s
antibody anti-phospho
ZAP70/SykTyr319/Tyr352
(mouse monoclonal)
ebioscience RRID:AB_2572664 clone: n3kobu5
antibody anti-phospho
ERK1/2Thr202/Tyr204
(mouse monoclonal)
BioLegend RRID:AB_2629710 clone: 6B8B69
antibody anti-phospho AKT1Ser473
(mouse monoclonal)
ebioscience RRID:AB_2573309 clone: SDRNR
antibody anti-phospho
S6Ser235, Ser236
(mouse monoclonal)
ebioscience RRID:AB_2572666 clone: cupk43k
antibody anti-phospho STAT5
(mouse monoclonal)
BD Biosciences RRID:AB_10894188 clone: 47/Stat5(pY694)
antibody anti-phospho Smad2
(pS465/pS467)/
Smad3 (pS423/pS425)
(mouse monoclonal)
BD Biosciences RRID:AB_2716578 clone: O72-670
antibody PerCP/Cy5.5-streptavidin BioLegend RRID:AB_2716577
recombinant
DNA reagent
pCR 2.1-TOPO (vector) Invitrogen CAT#: K204040
sequence-based
reagent
Foxp3 Intron1 Eton Bioscience Forward: ATTTGAATTGGATATGGTTTGT;
Reverse: AACCTTAAACCCCTCTAACATC
sequence-based
reagent
Foxp3 TSDR Eton Bioscience Forward: GTTTGTGTTTTTGAGATTTTAAAAT;
Reverse: AACCAACTTCCTACACTATCTATTA
sequence-based
reagent
Rara Eton Bioscience Forward: CCAGTCAGTGGTTACAGCACA;
Reverse: TAGTGGTAGCCGGATGATTTG
sequence-based
reagent
Rarb Eton Bioscience Forward: ACATGATCTACACTTGCCATCG;
Reverse: TGAAGGCTCCTTCTTTTTCTTG
sequence-based
reagent
Rarg Eton Bioscience Forward: CATTTGAGATGCTGAGCCCTA;
Reverse: GCTTATAGACCCGAGGAGGTG
sequence-based
reagent
Oligo(dT)12-18 Primer Invitrogen CAT#: 18418012
peptide,
recombinant
protein
CRIg-Ig Genentech PMID: 16530040
peptide,
recombinant
protein
Biotinylated CRIg-Ig this paper prepared by our
laboratory
peptide,
recombinant
protein
control Ig Genentech PMID: 16530040
peptide,
recombinant
protein
Biotinylated
control Ig
this paper prepared by our
laboratory
peptide,
recombinant
protein
CTLA-4 Ig R and D Systems CAT#: 434-CT-200/CF
peptide,
recombinant
protein
PD-1 Ig R and D Systems CAT#: 1021-PD-100
peptide,
recombinant
protein
VISTA Ig R and D Systems CAT#: 7005-B7-050
Continued on next page
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Continued
Reagent type
(species)
or resources Designation Source or reference Identifiers Additional information
peptide,
recombinant
protein
CD226 Ig R and D Systems CAT#: 4436-DN-050
peptide,
recombinant
protein
TIGIT Ig R and D Systems CAT#: 7267-TG-050
peptide,
recombinant
protein
BDC2.5 mimotope AnaSpec CAT#: AS-63774 Sequence: RTRPLWVRME
peptide,
recombinant
protein
Recombinant
Murine IL-2
PeproTech CAT#: 212–12
peptide,
recombinant
protein
Recombinant Human
TGF-b1
PeproTech CAT#: 100–21
commercial
assay or kit
ACK lysing buffer Lonza CAT#: 10-548E
commercial
assay or kit
Anti-PE microBeads Miltenyi Biotec CAT#: 130-048-801
commercial assay
or kit
LIVE/DEAD fixable
dead cell stain kits
Invitrogen CAT#: L34972; CAT#: L34966
commercial assay
or kit
Foxp3/Transcription
factor
staining buffer set
ebioscience CAT#: 00-5523-00
commercial assay
or kit
Phosflow
Lyse/Fix buffer
BD Biosciences CAT#: 558049
commercial assay
or kit
Phosflow
Perm buffer III
BD Biosciences CAT#: 558050
commercial
assay or kit
Percoll GE Healthcare Life
Science
CAT#: 17-0891-01
commercial
assay or kit
NucleoSpin
Tissue XS
Macherey-Nagel CAT#: 740901.50
commercial
assay or kit
EZ DNA
Methylaiton Kit
Zymo Research CAT#: D5001
commercial
assay or kit
HotStarTaq
DNA Polymerase
QIAGEN CAT#: 203203
commercial
assay or kit
TOPO TA Cloning Kit Invitrogen CAT#: K204040
commercial
assay or kit
TRIzol Reagent Invitrogen CAT#: 15596026
commercial
assay or kit
SuperScript III
Reverse Transcriptase
Invitrogen CAT#: 18080044
commercial
assay or kit
SYBR Green
PCR Master Mix
Applied Biosystems CAT#: 4309155
chemical compound,
drug
Collagenase P Roche CAT#: 11249002001
chemical compound, drug Collagenase D Roche CAT#: 11088882001
chemical compound,
drug
DNase I Sigma-Aldrich CAT#: DN25-1G
chemical compound,
drug
ATRA Sigma-Aldrich CAT#: R2625-50MG
chemical compound,
drug
BMS 493 Sigma-Aldrich CAT#: B6688-5MG
Continued on next page
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Reagent type
(species)
or resources Designation Source or reference Identifiers Additional information
chemical compound,
drug
Vancomycin Acros Organics CAT#: 296990010
chemical compound,
drug
Metronidazole Acros Organics CAT#: 210340050
chemical compound,
drug
Neomycin Fisher Scientific CAT#: BP266925
chemical compound,
drug
Ampicillin Sigma-Aldrich CAT#: A0166-25G
chemical compound,
drug
PMA Sigma-Aldrich CAT#: P1585-1MG
chemical compound,
drug
Ionomycin Sigma-Aldrich CAT#: I0634-1MG
chemical compound,
drug
Brefeldin A solution BioLegend CAT#: 420601
chemical compound,
drug
Fisher Healthcare
Tissue-Plus
O.C.T Compound
Fisher Scientific CAT#: 23-730-571
chemical compound,
drug
Avidin, HRP conjugate Invitrogen CAT#: 434423
chemical compound,
drug
1-Step Ultra TMB-ELISA
Substrate
Solution
Thermo Scientific CAT#: 34028
chemical compound,
drug
Stop Solution for
TMB Substrates
Thermo Scientific CAT#: N600
chemical compound,
drug
DAPI Invitrogen CAT#: D1306
software, algorithm FlowJo FlowJo, LLC RRID:SCR_008520
software, algorithm ImageJ NIH RRID:SCR_003070
software, algorithm BISMA software other RRID:SCR_000688 public website, BDPC
DNA methylation
analysis platform
Mice
B6 and NOD/Foxp3GFP mice (Haribhai et al., 2007) were purchased from Jackson laboratory. NOD
and NOD/BDC2.5/Thy1.1 mouse lines were obtained from Mathis-Benoist laboratory (Hill et al.,
2007). NOD/BDC2.5/Thy1.1 mice were further crossed to NOD/Foxp3GFP to generate NOD/
BDC2.5/Foxp3GFP/Thy1.1+ and NOD/BDC2.5/Foxp3GFP Thy1.1+ Thy1.2+ mice. B6/CRIg KO mice
were provided by Genentech (Helmy et al., 2006). NOD/CRIg KO mice were generated by crossing
B6/CRIg KO mice onto a NOD background for more than 10 generations. Speed-congenics was
used to facilitate the generation of NOD/CRIg KO mice. All mice were housed under specific patho-
gen free (SPF) conditions in our animal facility at University of California, San Diego, in accordance
with the ethical guidelines of the Institutional Animal Care and Use Committee.
Cell preparations
The pancreas was minced and digested in 10 ml phenol red-free Dulbecco’s modified Eagle’s
medium (DMEM) containing collagenase P (0.5 mg/ml) (Roche, Indianapolis, IN) at 37˚C on a 200
rpm shaker for 20 min. After digestion, single cells were filtered by passing through a 70 um cell
strainer and suspended in FACS staining buffer. Colon lamina propria (cLP) cells were prepared as
previously described. Briefly, the intestine was cut longitudinally and sliced into 0.2–0.5 cm pieces,
followed by incubating in 10 ml Ca2+/Mg2+ free HBSS containing 10% FBS, 15 mM HEPES, and 5
mM EDTA at 37˚C on a 200 rpm shaker for 20 min. The intestine fragments were further digested in
10 ml RPMI 1640 containing 5% FBS, Collagenase D (0.5 mg/ml) (Roche) and DNase I (0.05 mg/ml)
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(Sigma-Aldrich, Saint Louis, MO) at 37˚C on a 200 rpm shaker for 45 min. Samples were collected by
passing through a 70 um cell strainer. cLP cells were then purified on a 44/67% Percoll (GE Health-
care Life Science, Chicago, IL) gradient by centrifugation (800 x g, 20 min at room temperature). Sin-
gle-cell suspensions of lymphoid organs were prepared by mechanic disruption. Red blood cells
were lysated with Ammonium-Chloride-Potassium (ACK) buffer (Lonza, Walkersville, MD). Peritoneal
cells were collected by flushing 1 x PBS into the peritoneal cavity.
In vitro T cell activation
For T cell activation assays, 96-well tissue-culture plates were pre-coated with anti-CD3 (2.5 ug/ml)
and CRIg-Ig (5 ug/ml), or control Ig in 1 x PBS at 4˚C overnight. The plates were washed with 1 x
PBS three times. Single cell suspensions from spleen, peripheral lymph node were prepared. CD4+
CD25- cells were MACS (Miltenyi Biotec, Auburn, CA) enriched and labeled with CFSE or CTV. In
some experiments, CD4+ Foxp3(GFP)- Tconv cells were FACS sorted. Isolated Tconv cells (1  105/
well) were cultured in RPMI1640 supplemented with 10% FBS, L-glutamine (2 mM), penicillin (100 U/
ml), streptomycin (100 ug/ml), and non-essential amino acids (100 Um) and b-mercaptoethanol (50
uM), in the presence of soluble anti-CD28 (2.5 ug/ml). CRIg-Ig fusion proteins were pre-coated or
added as soluble form as indicated. In some experiments, anti-CRIg mAb (clone 17C9, or 14G8) was
added to the culture either in a soluble form, or pre-coated as indicated. To test the effect of cross-
linking of CRIg by anti-CRIg mAb, plates were pre-coated with different concentrations of anti-CRIg
mAb (clone 17C9), or isotype control mAb, and anti-CD3. Soluble anti-CD28 and soluble CRIg-Ig (5
ug/ml) were added to the cultured cells.
In vitro iTreg differentiation and restimulation
96-well tissue-culture plates were pre-coated with either CRIg-Ig (2.5 ug/ml), or control Ig. CD4+
Foxp3- Tconv cells were sorted from NOD/Foxp3GFP reporter mice, labeled with CFSE or CTV and
cultured (1  105) in the presence of plate-bound anti-CD3 (2.5 ug/ml), soluble anti-CD28 (2.5 ug/
ml), murine IL-2 (100 U/ml) and TGF-b (1 ng/ml or as indicated) for 3 days. In some experiments, an
anti-TGF-b neutralizing antibody (clone 1D11) was added. In antigen-stimulated Treg differentiation
assays, the plates were pre-coated with either CRIg-Ig (10 ug/ml), or control Ig. Total splenocytes (2
 105) from NOD/BDC2.5/Thy1.1 mice were labeled with CTV and cultured with mimotope (100 ng/
ml) (AnaSpec, Fremont, CA) for 3 days. Cells were then analyzed for the expression of GFP or intra-
cellular staining for Foxp3.
For the culture of restimulated iTreg cells, iTreg cells were generated by TGF-b, without CRIg-Ig.
After 24 hr, GFP (Foxp3)+ cells were sorted and restimulated under the condition of plate-bound
anti-CD3 (2.5 ug/ml), soluble anti-CD28 (2.5 ug/ml), IL-2 (100 U/ml), anti-TGF-b neutralizing antibody
(clone 1D11), with plate-bound CRIg-Ig (5 ug/ml) or control Ig, respectively. After 3 days, cultured
cells were collected and analyzed for the expression of GFP or intracellular staining for Foxp3. In
some experiments, purified Tconv cells were activated for 24 hr, washed and transferred to a new
plate with coated anti-CD3 (2.5 ug/ml), soluble anti-CD28 (2.5 ug/ml), IL-2 (100 U/ml) and TGF-b (1
ng/ml) and cultured for 3 days.
For in vitro Treg suppression assay, iTreg cells were generated as above with CRIg-Ig, or Control-
Ig, respectively. After 3 days, GFP (Foxp3)+ cells were sorted and co-cultured with MACS enriched
CTV labeled CD4+CD25- cells at the ratio of 1:4, 1:2 and 1:1, respectively, in the presence of plate-
bound anti-CD3, soluble anti-CD28 for 3 days.
In vitro macrophage culture
F4/80+ macrophages from peritoneal cavity were sorted as CRIg+ or CRIg- subsets and cultured in
complete DMEM in the presence of RA (100 nM) (Sigma-Aldrich) or control DMSO. After 3 days of
culture, adherent macrophages were harvested by adding Trypsin and EDTA (5 mM) and analyzed
for CRIg expression by FACS.
Adoptive cell transfer and in vivo treatments
For in vivo CRIg-Ig treatment, 10-week-old pre-diabetic NOD mice were i.p. injected with CRIg-Ig
(3.5 mg/kg) mixed with anti-CRIg mAb (17C9) (7 mg/kg) or control Ig (3.5 mg/kg), twice a week for
2 weeks. Pancreas and other lymphoid organs were analyzed after the treatment. For in vivo pTreg
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induction assays, CD4+ Foxp3(GFP)- Tconv cells were sorted from NOD/BDC2.5/Foxp3GFP/Thy1.1+
mice and i.p. transferred to 4-week-old NOD or NOD/CRIg KO mice. In some experiments, NOD
mice received adoptively transferred Tconv cells were injected with CRIg-Ig, or control Ig every other
day for 2 weeks. After 2 weeks, transferred cells collected from the pancreas and lymphoid organs
were analyzed. For in vivo iTreg stability assays, CD4+ Foxp3(GFP)- Tconv cells were sorted from
NOD/Foxp3GFP/Thy1.1+ mice, or NOD/Foxp3GFP/Thy1.1+ Thy1.2+ mice, and differentiated into
iTreg cells under conditions with plate-bound CRIg-Ig and control Ig respectively. iTreg cells from
these two conditions were sorted and mixed (2  105 each) at 1:1 ratio before transferring into 10–
14 days old NOD mice (Thy1.2+). One week later, transferred cells from spleen and pancreatic islets
were isolated and analyzed by flow cytometry. For antibiotics treatment, 8-week-old B6, or 10-week-
old NOD mice were given a combination of four antibiotics (vancomycin, metronidazole, neomycin
and ampicillin, VMNA) (Sefik et al., 2015) in drinking water supplement with sugar. Peritoneal cav-
ity, pancreatic and colonic macrophages were analyzed one week later. For in vivo treatment of
BMS 493 (Sigma-Aldrich), 7 weeks old B6 mice were i.p. injected with BMS 493 (100 nM) daily for 3
days. In some experiments, peritoneal cavity macrophages (3  104) were sorted from B6/CD45.1
mice and i.p. transferred into B6/CD45.2 mice, followed by BMS 493 treatment. Peritoneal and pan-
creatic macrophages were analyzed after the last injection.
Abs and flow cytometry
All stainings began with an incubation with a mAb for CD16/32 (2.4G2 BD Biosciences). mAbs to
indicated molecules used in this study were: Biotin-CRIg were prepared by our laboratory. CD45
(30-F11), CD45.1 (A20), CD45.2 (104), TCRb (H57-597), CD4 (RM4-5), CD8a (53–6.7), Thy1.1 (OX-7),
Thy1.2 (30-H12), Helios (22F6), CD122 (5H4), CD25 (PC61), CD69 (H1.2F3), F4/80 (BM8), CD11b
(M1/70), CD11c (N418), CD19 (6D5), NKp46 (29A1.4), IL-17 (TC11-18H10.1), and IFN-g (XMG1.2)
from BioLegend (San Diego, CA); ICOS (7E.17G9) and Foxp3 (FJK-16s) from eBioscience (San Diego,
CA) . PerCP/Cy5.5-streptavidin was from BioLegend. Intracellular staining of Foxp3 and Helios was
performed using Foxp3/transcription factor staining buffer set (eBioscience) according to the manu-
facturer’s instructions. For intracellular IFN-g and IL-17 detection, unfractionated cells were cultured
in complete medium in the presence of phorbol myristate acetate (PMA), and Ionomycin (Signa-
Aldrich) and Brefeldin A (BioLegend) at 37˚C for 4 hr. Samples were acquired with a BD LSRFortessa
(BD, San Jose, CA) and analyzed with FlowJo software (FlowJo, LLC, Ashland, OR).
Binding assays
CD4+ CD25- Tconv cells from 10-week-old NOD mice, or CD4+ GFP(Foxp3)+ Treg cells from 10-
week-old NOD/Foxp3GFP mice, were cultured under the in vitro T cell activation condition. At indi-
cated time-points, different concentrations of biotinylated CRIg-Ig or control Ig were incubated with
cultured T cells at 37˚C for 1 hr. Cells were then harvested and stained with Fixable Viability Dyes
(Invitrogen, Carlsbad, CA) before fixed with paraformaldehyde (1.6%). Streptavidin-conjugated sec-
ondary Abs were added to measure the binding intensities of biotinylated CRIg-Ig or control Ig.
Enzyme-linked immunosorbent assay
Flat bottom Costar 96-well plate were coated with 100 ul rat anti-mouse CRIg (clone 19E4, 1 ug/ml)
in 0.05 M Na2CO3 pH 9.6 at 4˚C overnight. Coated Plates were washed with 1 x PBS and blocked
with blocking buffer which contains 50 mM Tris, 0.14 M NaCl, and 1% BSA at 37˚C for 2 hr. Mice
sera were diluted (1:20) and 100 ul of sample was added to each well and incubated at 37˚C for 2
hr. After incubation, plates were washed with 1x PBS containing 50 mM Tris, 0.14 M NaCl, 0.05%
Tween 20, and incubated with 100 ul 1 ug/ml biotinylated anti-CRIg mAb (14G8) in blocking buffer
at 37˚C for 1 hr. After washing, plates were then incubated with diluted HRP-Avidin (1: 20,000)
(Invitrogen) at 37˚C for 1 hr. Plates were washed and incubated with TMB substrate at 37˚C for 30
min. Stop solution was added before plates were read on microplate reader at an optical density (O.
D.) of 450 nm (reference 570 nm).
Phosphorylation assays
CD4+ CD25- cells were cultured under the in vitro T cell activation conditions. At indicated time
pointes, the cells were fixed with paraformaldehyde (1.6%) for 10 min at 37˚C. Fixed cells were
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permeabilized with ice-cold methanol for 30 min, and stained with the phospho Abs for ZAP70Tyr319/
Tyr352 (clone n3kobu5; eBioscience), ERK1/2Thr202/Tyr204 (clone 6B8B69; BioLegend), AKT1Ser473 (clone
SDRNR; eBioscience) and S6Ser235/236(clone cupk43k; eBioscience) for 1 hr at room temperature. In
Treg phosphorylation assays, control or CRIg iTreg cells were prepared as above described. After 18
hr, iTreg cells were fixed, permeabilized, and stained with phospho Abs for AktSer473, S6Ser235/236.
For the analysis of phospho-STAT5, iTreg cells first rested in complete RPMI1640 medium for 30 min
and then incubated with murine IL-2 (100 U/ml) for 15 min at 37˚C. After that, the cells were fixed
and permeabilized as described above and subsequently stained with anti-phospho-STAT5 (clone
47/Stat5(pY694); BD Biosciences) for 1 hr at room temperature. To detect the phosphor Smad2/3,
total splenocytes from NOD mice were serum-starved overnight. CD4+ CD25- cells were then sorted
and cultured in medium with 0.2% of fetal bovine serum under iTreg differentiation condition. At
indicated time-points, cultured T cells were fixed in Phosflow Lyse/Fix Buffer (BD Biosciences) for 10
min at 37˚C and permeabilized in Phosflow Perm Buffer III (BD Biosciences) for 30 min on ice. Cells
were then stained with mouse anti-Smad2 (pS465/pS467)/Smad3 (pS423/pS425) (O72/
670; BD Biosciences) mAb for 1 hr at room temperature.
Immunostaining and histology
Tissue samples were cut and snap frozen in optimum cutting temperature (O.C.T., Fisher
Scientific, Houston, TX). 6 um cryo-sections of tissue sections were cut and fixed with pre-cold ace-
tone for 20 min. Immunostaining was performed as previously described (Fu et al., 2014). Before
adding primary mAbs, sections were blocked with 5% normal donkey serum (Jackson ImmunoRe-
search, West Grove, PA). The following mAbs were used in different combinations as indicated in
the figure legends: anti-CRIg mAb (a gift from Genentech, South San Francisco, CA); anti-F4/80
(BM8, BioLegend); anti-CD4 (RM4-5, BioLegend). Nuclei were stained with DAPI (4’,6-Diamidino-2–
28 phenylindole dihydrochloride) (Invitrogen). Images were acquired on an AxioImager microscope
(Zeiss, Thornwood, NY), and were processed with ImageJ (NIH). For histology assays, the pancreases
were removed and fixed with 10% formalin solution. Fixed tissue blocks were paraffin-embedded,
sectioned, and stained with haematoxylin and eosin.
Bisulfite sequencing
Genomic DNA was extracted by using NucleoSpin Tissue XS (Macherey-Nagel, Bethlehem, PA) and
bisulfite converted by using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA). Foxp3 CNS2
region was amplified by PCR containing 5 ng of bisulfite-converted genomic DNA, HotStar Taq PCR
buffer (QIAGEN, Valencia, CA), 0.5 U HotStar Taq DNA polymerase, 2.5 mM MgCl2 and 0.38 mM
each of forward and reverse primers (Ohkura et al., 2012; Yang et al., 2016) in a final volume of 25
ml (95˚C for 10 min; 40 cycles: 95˚C for 30 s, 58˚C for 1 min, 72˚C for 1 min; 72˚C for 5 min). The PCR
product was analyzed by gel electrophoresis and TA cloned using TOPO TA Cloning Kit (Invitrogen)
and One Shot TOP10 Chemically Competent E. coli. Colonies were picked and submitted for direct
colony sequencing. Sequencing results were analyzed on Bisulfite Sequencing DNA Methylation
Analysis website (Rohde et al., 2010).
Real time RT-PCR
CRIg+ and CRIg- macrophages from the peritoneal cavity of 7-week-old B6 mice were FACS sorted.
Total RNA was extracted using Trizol and reverse-transcribed using oligo(dT) and SuperScript III
(Invitrogen). PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA), using CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA) for
PCR and signal detection. The primers were: Rara forward: ccagtcagtggttacagcaca. Rara reverse:
tagtggtagccggatgatttg. Rarb forward: acatgatctacacttgccatcg. Rarb reverse: tgaaggctccttctttttcttg.
Rarg forward: catttgagatgctgagcccta. Rarg reverse: gcttatagacccgaggaggtg.
Statistics
Student’s t-test was used for statistical analyses. P values of 0.05 or less were considered statistically
significant.
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